Metagenomi's Upcoming Presentations at Leading Scientific Conferences
Metagenomi, Inc. (Nasdaq: MGX), a pioneering force in precision genetic medicine, is set to share its innovative approaches and advancements in the field through multiple presentations at highly regarded scientific conferences. The company is dedicated to developing curative therapeutics utilizing its unique gene editing toolbox, a cornerstone of their mission to serve patients effectively. This month, Metagenomi will be featured at two prestigious events, showcasing its latest research and findings.
Insights from TIDES USA Conference
The first highlight will be an oral presentation at TIDES USA, a significant gathering in the domain of RNA and gene therapies, scheduled for May 22, 2025. This keynote will focus on their AI-driven metagenomic discovery process, concentrating on compact CRISPR systems aimed at therapeutic genome editing.
Details of the Oral Presentation
Title: AI-Guided Metagenomic Discovery of Compact CRISPR Systems for In Vivo Therapeutic Genome Editing
Session: Genome Editing Technologies and Applications
Location: Mission Beach Room
Date and Time: Thursday, May 22, 2025, at 2:30 PM PST
Innovative Contributions at ASGCT Annual Meeting
Following TIDES, Metagenomi will also be presenting three posters at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place from May 13 to 17, 2025. This platform will allow the team to share insights into groundbreaking research focusing on in vivo genome editing technologies.
Poster Presentation Highlights
Title: In Vivo Genome Editing with an Ultra-Compact Type V Nuclease for All-In-One AAV Delivery
Abstract Number: AMA2219
Location: Poster Hall I2
Date and Time: Tuesday, May 13, 2025, at 6:00 PM CT
Title: Site-Specific Integration of Therapeutic Transgenes with a Type V-K CAST System Engineered for Efficient and Targeted Human Genome Editing
Abstract Number: AMA2184
Location: Poster Hall I2
Date and Time: Tuesday, May 13, 2025, at 6:00 PM CT
Title: A Compact and Potent Type II CRISPR System for CNS Gene Knockdown via AAV Delivery
Abstract Number: AMA1232
Location: Poster Hall I2
Date and Time: Tuesday, May 13, 2025, at 6:00 PM CT
Accessing Presentations and Company Updates
After the conferences, attendees can find all presentations made by Metagenomi on their official website's "News & Events" section for investors. The commitment to transparency and accessibility highlights Metagenomi's focus on keeping stakeholders informed and engaged with their research.
About Metagenomi
Metagenomi prides itself on being at the forefront of genetic medicine innovation. By harnessing the capabilities of metagenomics, the company taps into four billion years of microbial evolution to develop sophisticated and versatile genome editing tools. Their extensive toolbox includes programmable nucleases, base editors, and other novel systems that facilitate targeted genetic modifications in human cells. This innovative platform offers the potential for addressing a wide array of genetic mutations, aligning with their mission to enhance patient outcomes through cutting-edge therapy.
Frequently Asked Questions
What is Metagenomi's primary focus?
Metagenomi focuses on developing curative therapeutics using its proprietary gene editing tools, enhancing treatment for various genetic conditions.
Where and when will Metagenomi present its research?
Metagenomi will present at TIDES USA on May 22, 2025, and at the ASGCT Annual Meeting from May 13 to 17, 2025.
What is the significance of their oral and poster presentations?
These presentations aim to showcase their advancements in genome editing technologies, emphasizing innovative approaches to therapeutic solutions.
How can stakeholders access Metagenomi's presentations?
Presentations will be available on the Metagenomi website within the "News & Events" section under the Investors tab.
What sets Metagenomi apart in the genetic medicine field?
Metagenomi distinguishes itself with its AI-driven metagenomics platform and modular toolbox, enabling targeted and efficient genetic modifications across the genome.
